The U.S. Food and Drug Administration (FDA) has approved Abeona Therapeutics’ gene therapy, Zevaskyn (prademagene zamikeracel), for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare and…
Home » RDEB
The U.S. Food and Drug Administration (FDA) has approved Abeona Therapeutics’ gene therapy, Zevaskyn (prademagene zamikeracel), for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare and…